Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.
Luca QuartuccioArianna SonagliaDavide PecoriMaddalena PeghinMartina FabrisCarlo TasciniSalvatore De VitaPublished in: Journal of medical virology (2020)
Repeated measurement of the serum level of IL-6 early after tocilizumab may distinguish nonsurvivors from survivors and support the choice of deeper targeting IL-6 in COVID-19 pneumonia.